Newsroom
Post Market Movers: Adaptive Biotechnologies (ADPT) Q2 Earnings: A Deep Dive into Financial Results
By KlickAnalytics Data Insights | August 1, 2024 08:10PM ET
Key Points
- Adaptive Biotechnologies (ADPT) reports a quarterly loss of $0.26 per share
- Revenue for the quarter ended June 2024 exceeds Wall Street estimates
- Comparison of key metrics with year-ago numbers showcases performance trends
- Adaptive Biotechnologies aims to translate adaptive immune system genetics into clinical products
- The company's financial results for Q2 2024 were released on August 1, 2024
Adaptive Biotechnologies Corporation, a biotechnology company focused on translating the genetics of the adaptive immune system into diagnostic and therapeutic products, recently announced its financial results for the quarter ended June 30, 2024. Despite reporting a quarterly loss of $0.26 per share, the company managed to outperform the Zacks Consensus Estimate of a loss of $0.32 per share.
The revenue generated by Adaptive Biotechnologies in the second quarter of 2024 exceeded Wall Street estimates, indicating positive growth and potential business performance. This success in revenue highlights the company's ability to adapt and thrive within its industry, even amidst challenging market conditions.
Comparing key metrics from the recent quarter with both Wall Street estimates and the year-ago numbers provides valuable insights into the company's overall performance trends. By analyzing these metrics, investors and analysts can better understand how Adaptive Biotechnologies is navigating the evolving market landscape and positioning itself for future success.
Adaptive Biotechnologies continues to focus on leveraging the genetics of the adaptive immune system to develop innovative clinical products for diagnosing and treating diseases. This strategic approach underscores the company's commitment to advancing healthcare solutions and making a meaningful impact on patient outcomes through cutting-edge technology and research.
In conclusion, Adaptive Biotechnologies' second-quarter financial results reflect a mixed performance, with a quarterly loss slightly beating expectations and revenue surpassing estimates. The company's ongoing efforts to leverage immune system genetics for clinical applications position it well for future growth and success within the biotechnology sector.
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with